Clinical Trial Update: MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating MRG003 in combination with immunotherapy for recurrent/metastatic nasopharyngeal carcinoma, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• MRG003

Snippet

Sponsor: West China Hospital | Conditions: Nasopharyngeal Cancinoma (NPC) | Phase 2 | Status: NOT_YET_RECRUITING